Overview

Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects

Status:
Completed
Trial end date:
2019-05-03
Target enrollment:
Participant gender:
Summary
To study the pharmacokinetic profiles of decitabine and tetrahydrouridine (THU) from 3 modified release formulations in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
EpiDestiny, Inc.
Treatments:
Azacitidine
Decitabine
Tetrahydrouridine